Kiniksa Pharmaceuticals International, plc reported Q2 2025 net product revenue of $156.8 million, a 52% year-over-year growth. Expected net product revenue for 2025 increased to $625-$640 million. Phase 2/3 clinical trial for KPL-387 in recurrent pericarditis initiated, with Phase 2 data expected in 2H 2026. Cash balance increased to $307.8 million in Q2 2025. Conference call scheduled for 8:30 am ET today.

ARCALYST net product revenue in Q2 2025 was $156.8 million, with over 3,475 prescribers writing prescriptions for recurrent pericarditis. Average duration of therapy was around 30 months. Approximately 15% of the target 14,000 patients were actively on ARCALYST treatment by the end of Q2 2025.

KPL-387 Phase 2/3 clinical trial in recurrent pericarditis is recruiting patients, with data expected in the second half of 2026. Kiniksa is conducting IND-enabling development activities for KPL-1161, with a target profile of quarterly subcutaneous dosing.

Total revenue for Q2 2025 was $156.8 million, compared to $108.6 million in Q2 2024. Operating expenses were $136.6 million, with net income of $17.8 million for Q2 2025. Cash, cash equivalents, and short-term investments as of June 30, 2025, were $307.8 million.

Kiniksa expects 2025 ARCALYST net product revenue to be between $625 and $640 million, up from prior guidance. The company anticipates its current operating plan to remain cash flow positive annually. A conference call and webcast to discuss financial results and portfolio execution will be held at 8:30 am ET today.

Read more at GlobeNewswire: Kiniksa Pharmaceuticals Reports Second Quarter 2025